Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — New York Publishes Sample Job Descriptions to Help Employees, Companies in Legal Cannabis Industry

The state of New York’s labor department recently published sample job descriptions for various positions in the marijuana industry. Their intention is to allow prospective employees to evaluate their qualifications to work in different roles in the growing industry while also helping firms streamline hiring processes.

In a statement, a representative of the department said that marijuana’s legalization had created significant opportunities, and the department of labor was committed to supporting businesses as well as those seeking employment in the state as the industry continued to expand. The department began posting the sample descriptions earlier this month. They include example positions in delivery, cultivation, retail, and product manufacturing and hospitality as well as sampling and testing jobs.

Some positions are entry level, such as managing retail inventory or trimming, while others require skilled individuals for roles such as cannabinoid extraction, management or laboratory testing. The job-description samples are posted on the department’s Cannabis Career Exploration site and are meant to be used as education resources for those seeking employment. The website also includes a page on how to find cannabis jobs and links to marijuana education opportunities.

The department also released a statement noting that this online resource was put together to help New Yorkers explore working in the marijuana industry. It further noted that the resource would also help those seeking employment to evaluate their skills to find a focus area and determine what education or training they would need to succeed in their chosen careers. The department then added that the resources could be used as a starting point for businesses as they start hiring their workforce.

The sample postings come just weeks after the state’s Supreme Court lifted an injunction that prohibited state cannabis regulators from processing new retailer licenses. This move will allow the New York marijuana market to expand significantly.

In a press release, the Cannabis Control Board’s chair Tremaine Wright stated that the decision brought relief to hundreds of those with provisional licenses whose businesses had been sidelined. Wright then noted that the board remained focused on upholding a transparent and fair process as it continued to support and grow the state’s marijuana industry.

New York Governor Kathy Hochul also wrote on social media that the decision by the supreme court meant there should be more places to buy tested, safer and legal marijuana stores would launch faster. Currently, however, there fewer than 30 licensed retailers for adult-use cannabis in the state.

It is expected that the court’s decision will also reduce the number of illicit operators in the market, who currently make up a significant fraction of the marijuana market.

Marijuana industry actors elsewhere, including group leader Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), are likely to welcome the steps that are being taken to get the industry finally going in New York State since the state has faltered several times in its attempts to roll out regulated sales.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Ukraine Lawmakers Pass Bill Legalizing Medical Cannabis, Send to President’s Desk

Legislators in Ukraine recently gave their final approval for a measure that will legalize the use of medical cannabis nationally. The measure has been forwarded to President Volodymyr Zelensky’s desk, who is in favor of reform, to be signed into law. The law shall come into effect six months after the president signs it.

The measure will legalize medical marijuana use for patients diagnosed with serious illnesses and PTSD linked to the country’s ongoing war with Russia. Russia invaded Ukraine in February 2022, with experts noting this was an escalation of the Russo-Ukrainian war, which began in 2014.

In order to obtain the needed approval for the legalization, a petition calling for special procedure, which needed the signatures of 150 members, was circulated. Olga Stefanyshina, a member of Parliament, revealed recently that a total of 164 signatures were collected, which cleared the way for the bill’s passage. It should be noted that the bill’s language explicitly lists war-borne, post-traumatic stress disorder and cancer as the only eligible conditions qualifying patients to receive medical marijuana.

Despite this, the health committee’s chair revealed earlier in the year that legislators heard daily from individuals with other ailments, including epilepsy and Alzheimer’s disease. The measure’s approval reschedules marijuana from a List I drug to a List II drug. While drugs under the former category are strictly prohibited, those in the latter category are available for therapeutic use if one has a prescription.

It is expected that the Ministry of Agrarian Policy will have regulatory authority with regard to marijuana cultivation as well as processing operations. On the other hand, the State Agency on Medicines and the National Police will oversee and enforce authorities associated with the drug’s distribution.

The bill also permits the import of raw marijuana materials from other nations, in an effort to ensure patient access.

In a translation, MP Maria Mezentseva stated that the government leaders had accounted for the various fundamental issues emphasized by colleagues and that it was crucial to not trust fake information that was making the rounds on various social media platforms. Mezentseva added that the law on medicinal marijuana was aimed solely at providing treatment for nationals who truly needed it.

The president discussed his stance on medical cannabis legalization earlier this year. During his address to parliament, Zelensky stated that the most effective policies as well as the best practices and solutions needed to be applied in the country, so Ukrainians didn’t have to endure the stress, pain and trauma of war. He also noted that fairly legalizing marijuana-based medicines for all those who needed them, with appropriate scientific study and controlled production, was key.

Companies such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) could explore supplying some of the needed medical marijuana products to Ukraine since they already have some experience availing these products to a number of markets within the EU bloc.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Shows State-Level Cannabis Legalization Boosts Recruitment for College Basketball

A recent study conducted by researchers at Kennesaw State University and Georgia College and State University has established a link between cannabis legalization and its impact on recruitment outcomes for college sports teams. Delving into the dynamics of recreational marijuana policies and their influence on talent acquisition, the researchers examined recruiting data spanning from 2003 to 2019.

Their findings, presented in the “Sports Economics Journal,” propose that cannabis legalization plays a major yet intricate role in shaping the landscape of college sports recruitment, particularly in football and basketball, warranting attention from NCAA leagues. The research revealed a positive correlation between cannabis legalization and enhanced recruitment prospects for college basketball teams. Teams situated in states where marijuana is legal experienced an average improvement of 3.7 slots in recruiting rankings. In stark contrast, the outcomes for football teams in legal states were less favorable, with recruitment rankings showing an average decline of 2.9 slots compared to similar institutions in nonlegal states.

Despite the absence of survey data from individual athletes, the authors caution against drawing definitive conclusions from their findings. Nonetheless, they offer speculative hypotheses to shed light on the observed disparities. One theory posits that variations in the recruitment landscape between football and basketball may be attributed to the historical cannabis policies of national leagues, such as the NBA and NFL. The NFL, with its more stringent penalties for marijuana use, could have instilled greater caution among college football players compared to their basketball counterparts.

The study notes the evolving landscape of league policies, citing adjustments made by both the NFL and NBA in 2020. The NBA, for instance, removed cannabis from its banned substances list, allowing players to engage in marijuana-related activities within specified limits. Similarly, the NFL altered its drug-testing policy to eliminate the threat of suspension for positive tests, signaling a more lenient stance.

Notably, the study highlights the broader impact of cannabis policy changes on various professional sports leagues, including the NCAA. In a significant move, the NCAA Committee on Competitive Safeguards and Medical Aspects of Sports recommended the removal of cannabis from the list of banned substances for college athletes. This proposed reform aligns with the NCAA’s prior adjustment of the THC threshold for a positive test, bringing it in line with the WADA standards.

The researchers also explore the possibility that the disparate effects of legalization on football and basketball recruitment may be influenced by cultural differences within these sports communities. The study suggests that the basketball community might be more accepting of cannabis use, potentially empowering college recruits to choose institutions in states where recreational use is permitted.

The researchers acknowledge the need for further research to validate these hypotheses. However, they emphasize the predictive power of their results in anticipating the future dynamics of college athletics. With several states enacting legalization post-2019, the study suggests that colleges in these states may witness improved basketball recruitment and on-court performance but could experience adverse effects on football recruitment and on-field performance in the coming years.

Established cannabis companies such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) likely wouldn’t have thought that the legalization of cannabis could have positive effects on recruitment into college sports teams. More research could reveal yet more benefits associated with ending cannabis prohibition.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Suggests CBD-Infused Tampons Could Be Effective Against Menstrual Pain

A recent study published in the “Endometriosis and Uterine Disorders” Journal has unveiled promising results regarding CBD-infused tampons for alleviating menstrual pain and severe cramps. The study’s authors posit that these CBD-infused tampons may present a more favorable option with fewer side effects compared to traditional anti-inflammatory medications, offering a parallel pain-relieving impact.

The research team, comprised of six researchers, noted the following in their report: “The outcomes suggest that CBD-infused tampons hold potential as an effective solution for managing menstrual pain.” They emphasized the necessity for further exploration and research into the product, asserting its potential contribution to addressing primary dysmenorrhea, a condition characterized by painful muscle cramps and spasms affecting between 50% and 90% of menstruating women.

The study examined the relationship between CBD, CB2 and CB1 receptors, claiming that because these receptors are extensively dispersed throughout uterine tissue, they provide an ideal target for the localized administration of cannabinoids to reduce pain. A randomized, placebo-controlled methodology was used to conduct the study, and participants were not informed whether they were using a regular or CBD-infused tampon. Participants self-reported their pain thresholds and general levels of satisfaction.

The study group carefully investigated a number of factors, such as systemic toxicity, vaginal irritation, material-mediated pyrogenicity, sensitization, and possible risk of toxic shock syndrome. They confirmed that every test was passed with success, demonstrating the safety of tampons infused with CBD.

Regarding pain alleviation, the report indicated a noteworthy percentage change, reaching 100% in the last menstruation days. Additionally, the study demonstrated a statistically significant decrease in discomfort during particular days of the menstrual cycle, two hours after tampon application.

Although fewer than 5% of participants reported experiencing irritation as a result of using CBD-infused tampons, between 37% and 40% reported an improvement in their vaginal dryness. Two patients reported vertigo while using the product; however, the symptoms cleared promptly without the need for medical treatment after removing the tampon.

The study’s lead author, Valentina Milanova, who also serves as CEO of Daye, a gynecological research company that claims to offer the first CBD-infused tampon worldwide, stated that the observed alleviation of primary dysmenorrhea throughout the menstrual cycle supports the potential effectiveness of CBD-infused tampons. All authors have financial ties to Daye’s parent company, Anne’s Day Ltd., based in London.

The authors did note the study’s shortcomings, particularly its small sample size, and urged future research and improvements to the research design, including the use of a crossover design to collect full pain data.

Cannabis research is still relatively in its infancy, but as the years go by, much more is likely to be known about the health and wellness benefits of the marijuana products currently commercialized by entities such as SNDL Inc. (NASDAQ: SNDL).

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Florida GOP Senator Files Medical Cannabis Bill for 280E Relief

Last week, a senator in Florida introduced a measure that would allow licensed medical-cannabis businesses to claim tax deductions. At the moment, legal marijuana businesses in the country aren’t allowed to claim deductions because of section 280E of the IRS code, which bars deductions from being claimed for illicit substances.

Section 280E prohibits businesses from deducting business expenses from gross income linked to the trafficking of Schedule I or II drugs. Currently, marijuana is still classified under Schedule I of the Controlled Substances Act. The measure, filed by GOP senator Ana Maria Rodriguez, would add Florida to a growing list of other states that have established tax parity for the marijuana industry.

The bill would amend the state’s tax code by permitting medical-marijuana operators to claim deductions in amounts equal to expenditure eligible to be claimed as federal income tax deductions. It should be noted that this measure would only extend relief to state medical-marijuana businesses.

Other states that have taken similar steps include Pennsylvania, whose House passed a sweeping tax reform measure in October containing language offering state relief to medical-cannabis businesses. The proposal hasn’t been fully accepted by GOP members, who see it as a giveaway by Democrats to the marijuana industry.

In November, New York’s governor signed a measure offering tax relief to cannabis businesses in the state. This comes after a budget measure enacted in 2022 included provisions to broadly permit state-level marijuana business tax deductions. Maine’s governor had, in August, signed a resolution decoupling state tax from the federal policy for marijuana businesses.

Earlier in June, Connecticut’s governor signed a budget measure that included provisions offering state-level tax relief to licensed cannabis businesses as a workaround for the industry. That same month, the governor of Illinois signed a budget measure that included provisions permitting licensed cannabis businesses to claim tax deductions that they’re currently barred from utilizing under Section 280E. In May, the governor of New Jersey also signed a bill that would permit licensed cannabis businesses to deduct some expenses on their tax returns as a partial fix.

At the congressional level, Representative Earl Blumenauer reintroduced a measure that would amend the code to permit state-legal cannabis businesses to claim tax deductions that are available to businesses operating in other industries. In an interview, Blumenauer explained that allowing state-legal businesses to fully deduct their business expenses would result in additional revenue collection because individuals would comply with the law.

This growing wave of states seeking ways to give the cannabis industry tax relief at the state level could afford enterprises such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) a breather that allows them to bring more innovative products to the market.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Ohio Marijuana Sector in Limbo as Lawmakers Close for the Year

Last week marked the conclusion of the Ohio Senate and House’s final scheduled sessions for the year, yet the anticipated progress on cannabis legislation remained elusive. Despite both chambers convening on Wednesday, no cannabis-related bills were discussed, prompting questions about the proximity of a consensus between the Senate and House on the matter.

Senate president Matt Huffman expressed uncertainty about the progress, noting that it was “challenging to determine. The provisions we endorsed, developed in collaboration with the governor and presented to the House have not received significant feedback.”

In a bipartisan move, the Senate passed HB 86, advocating for a 15% increase in cannabis tax, capping home cultivation at six plants, restructuring revenue distribution and integrating automatic expungement. Governor Mike DeWine urged swift legislative action, emphasizing the urgency for signing the measure into law. However, the House exhibited a less urgent approach, leaving DeWine disappointed.

Although cannabis is legal in Ohio, the absence of legal avenues for recreational purchases remains a challenge. The existing law empowers the state’s commerce department to formulate regulations and issue licenses, a process delayed until at least nine months after Nov. 7, 2023. Consequently, legal cannabis sales in Ohio might not materialize until well into the following year.

HB 86 presents an opportunity to expedite this timeline, allowing Ohioans to access recreational cannabis at dispensaries promptly upon the bill’s enactment. Senate Minority leader Nickie J. Antonio noted the importance of making safe, legal products available as soon as possible.

Huffman expressed concerns that the cannabis legislation’s progress might stagnate, particularly with the looming March 19, 2024, primaries. Fearing a potential delay into April and beyond, Huffman stressed the need for elements in the bill that were agreeable to the House.

Both Huffman and Antonio advocated for a dialogue between the Senate and House to discuss various aspects of the legislation. Meanwhile, House speaker Jason Stephens asserted that cannabis discussions would persist, noting the absence of significant hurdles in reaching a consensus within the chamber.

Three critical components of the proposed cannabis law include determining permissible usage locations, issuing licenses and outlining revenue utilization. State Representative Jamie Callender introduced HB 354, clarifying certain aspects of Issue 2. The bill maintains the existing home cultivation limits and specifies that cultivation must occur at a residential address.

As legislative discussions continue, with HB 354 undergoing three hearings in the House Finance Committee, the Senate and the House are scheduled to reconvene next month. Established cannabis companies such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) are likely to follow how matters evolve in this latest state to legalize recreational marijuana.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Investment Bank Expects Cannabis to Draw Millions of Customers from Alcohol

Analysis by a multinational investment bank has found that cannabis has grown into a “formidable competitor” to alcohol and will draw tens of millions of users over the next five years while alcohol loses several million drinkers. The TD Cowen analysis estimates that marijuana sales will hit a whopping $37 billion in 2027 as more states legalize cannabis and launch legal sales.

Alcohol has been the main drug of choice for most Americans for nearly a century, but the beverage has been fielding increasing competition from cannabis in recent years. With 24 states legalizing recreational cannabis so far, tens of millions of Americans now have access to legal cannabis. Several more states are considering cannabis reform and will most likely legalize the drug over the decade, increasing access to marijuana to even more Americans.

TD Cowen’s Cannabis Beats Booze report notes that the cannabis category will gain 19 million past-month consumers over the next five years while the alcohol category will lose two million. Lead of the analysis team Vivien Azer says the report adds to a growing body of market research that has consistently pointed to cannabis as a disclocator to alcohol sales. She said the team was surprised to see an “even greater underperformance” in the alcohol category in states with legal cannabis markets.

Although alcohol sales are still far ahead of cannabis sales, analysts say the beverage faces a risk of decline as an increasing number of consumers, especially younger people, are substituting alcohol with alternatives such as cannabis. Prior studies have found that younger populations are drinking less alcohol and using substitutes such as cannabis and psychedelics.

The report estimated that states such as Ohio and Minnesota, which recently legalized recreational cannabis but are yet to implement cannabis laws, could bring in an additional $37 billion in sales in 2027.

Alcohol companies may have little trouble navigating the evolving customer trends in the short-term, but certain brands likely face “competitive challenges” in the medium- and long-term.

TD Cowen says alcohol would keep underperforming in states with legal cannabis markets with beer being the most at-risk beverage. On average, TD Cowen notes, the number of drinks taken on given occasions is lower in legal cannabis states.

Despite the impact cannabis legalization seems to have had on alcohol consumption in legal states, Azer doesn’t see alcohol companies entering the marijuana market until there is meaningful administrative or legislative regulatory change at the federal level.

As more people opt for marijuana in lieu of alcohol, cannabis product demand will increase, and ancillary entities such as Innovative Industrial Properties Inc. (NYSE: IIPR) could also see their businesses grow as a result of this boom.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Interest in Growing Cannabis Grows in Ohio After Legalization Law Takes Effect

Ohio became the 24th state to legalize recreational cannabis in America after a voter-approved recreational marijuana initiative took effect. But, even though adults aged 21 years and older are now allowed to possess up to 2.5 ounces of cannabis flower and 1.5 grams of marijuana extract, the state has no authorized cannabis retailers.

Additionally, the state Division of Cannabis Control won’t start to process cannabis retailer applications until June 2024, meaning Ohio residents won’t have an avenue for legal adult-use purchases until late summer or even early fall.

The silver lining is that the cannabis legalization measure allows eligible Ohioans to cultivate up to six cannabis plants per household. Although the measure allowed up to 12 plants for a home with more than one eligible adult, a state senate bill reduced this limit to just six plants for every household. Ohio Governor Mike DeWine argued that the six plants per household allowed by Issue 2 were already more than a single person could consume alone.

For most Ohioans who want to consume cannabis in the meantime, home growing is the only legal means of doing so. Cannabis plants are fast growing and take three to four months to mature and bud. According to Cali Vybe Hydroponics from Finneytown, many more people have expressed interest in its products since Issue 2 passed and legalized recreational cannabis in Ohio.

For many, home cultivation provides a way to avoid pricey cannabis products from licensed shops and reduces the risk of consuming contaminated marijuana. Ohio Department of Commerce director Sherry Maxfield estimates that a mature homegrown cannabis plant can produce between 75 and 100 joints, meaning a sophisticated grower can yield significant cannabis in just a single year.

The fact that Ohio doesn’t have any authorized cannabis sellers despite legalizing recreational cannabis worries Senate President Matt Huffman because it could open the door for illicit sellers to carve out a market for themselves. Most states with cannabis markets, including California, which has the largest legal cannabis market on the globe, are struggling to compete with the cannabis black market.

Without a place to buy legal cannabis, many Ohioans may opt for the black market, especially since Issue 2 allows landlords to prohibit home-cannabis cultivation on their properties if it is specified on the lease. Cannabis from licensed sellers is several times more expensive than black-market marijuana due to numerous fees and taxes, resulting in reduced legal sales and a bountiful cannabis black market.

As this new market takes shape, it could easily attract established companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) that may be considering expanding into additional markets.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Superior Drug and API Delivery with Patented DehydraTECH Technology

Lexaria, a global innovator in drug delivery platforms, has made incredible strides in 2023, most recently seeing interim results from its human pilot study evaluating its DehydraTECH(TM) technology for the oral delivery of GLP-1 drug, semaglutide
The company has also grown its patent portfolio to 37, with many others pending worldwide
For 2024, the company expects to maintain the same momentum, building on the success and achievements, and plans to double down on licensing its technology

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in this past year, has demonstrated growing success in providing healthier delivery methods of drugs and other Active Pharmaceutical Ingredients (“APIs”), facilitated by its patented DehydraTECH(TM) technology. This has been driven by the company’s research efforts throughout 2023 and ambitious plans for 2024.

“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” noted Chris Bunka, Lexaria’s CEO (https://cnw.fm/OD1xJ).

So far in the 2023 calendar year, Lexaria has realized interim results from its human pilot study evaluating DehydraTECH for the oral delivery of glucagon-like peptide-1 (“GLP-1”) drug, semaglutide. It also held a successful pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) that would set the stage for its application in 2024 and the ultimate approval of its DehydraTECH-processed CBD. Lexaria also grew its patent portfolio to 37, with many other patents pending worldwide (https://cnw.fm/LY30U).

Entering 2024, the company plans to maintain the same momentum. Within the first quarter of the 2024 calendar year, it plans to file its Phase 1(b) Investigational New Drug (“IND”) application with the FDA for DehydraTECH-processed CBD as a prospective registered treatment for hypertension. It also plans to commence patient dosing for this study and conduct animal and human clinical studies to examine DehydraTECH-processed GLP-1 drugs used in products alone or with DehydraTECH-CBD.

Lexaria also plans to double down on licensing its technology, particularly since it promises a substantial commercial opportunity. Its exclusive global collaboration and license agreement with SulfoSyn Limited, for instance, will allow the company to generate revenue from its DehydraTECH technology while also further demonstrating its versatility and overall effectiveness in applications across the board (https://cnw.fm/1T7WG). So far, the technology has proven applicable in cannabinoids, oral nicotine, diabetes and weight loss, PDE5 inhibitors, and antiviral drugs, among others.

With the steps taken so far, Lexaria is projected to post a 259% year-over-year (“YOY”) revenue growth for 2024 and a 20% YOY growth for 2025, according to a Zacks SCR report (https://cnw.fm/Z0LWX). This growth progression will largely depend on the ultimate approval and commercialization of products utilizing DehydraTECH, which is currently on track.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Feds Pour Cold Water on Efforts by Georgia to Sell Medical Cannabis in Pharmacies

Georgia’s ambition to become the first state to allow pharmacies to distribute medical-cannabis products faces a setback as the DEA issued a stern warning. On Nov. 27, 2023, the agency cautioned pharmacies that dispensing medical cannabis violates federal law, urging Georgia to reconsider its plans.

The state’s pharmacy board, which initiated the acceptance of applications for dispensing medical cannabis products in October, has already granted licenses to 23 pharmacies in the state. The state’s medical marijuana commission, GMCC, acknowledges the federal directive. Despite state law permitting pharmacies to dispense medical marijuana, the commission, under the leadership of Andrew Turnage, cannot override the federal warning. Turnage expressed the state’s desire to continue allowing pharmacists to provide consultations for medical marijuana, paralleling their role with other medications.

According to the DEA’s memorandum to pharmacies, handling or dispensing cannabis or related products containing more than 0.3% THC is deemed unlawful. While Georgia allows medical-cannabis patients to purchase cannabis products containing up to 5% THC, the agency categorizes products exceeding 0.3% THC content as illegal under federal law.

Since 2015, Georgia has permitted patients with certain illnesses, sanctioned by physicians, to possess and consume low-THC medical-marijuana products. However, legal acquisition of the product within the state’s borders only became possible in April this year.

Nationwide, 24 states have legalized cannabis for recreational use, and an additional 23 allow medical marijuana, according to the National Conference of State Legislatures.

The recent DEA notice, disseminated online by the anti-legalization group Smart Approaches to Cannabis, prompted varied reactions. Some responses, such as the one from Ira Katz of Little Five Points Pharmacy, indicate pharmacies should be allowed to dispense medical-cannabis products akin to marijuana dispensaries. Conversely, Mahlon Davidson, interim CEO of the Georgia Pharmacy Association, expressed skepticism about independent pharmacists jeopardizing their businesses by contravening the DEA’s directives.

Opponents of recreational and medical cannabis legalization argue that the DEA’s directive serves to protect consumers and allows for further research. Michael Mumper, executive director of the nonprofit Georgians for Responsible Cannabis Policy, emphasized the trust consumers place in drugs dispensed from pharmacies, highlighting FDA approval and federal legality, aspects he contends are lacking in medical cannabis.

The federal perspective might transform with a recent proposal seeking to ease restrictions on cannabis. The HHS recommended removing cannabis from Schedule I to Schedule III in August. The decision on this currently lies with the DEA, which is in charge of controlling substance classification in the United States.

The success of pharmacies in Georgia selling medical cannabis could have provided an interesting channel that would have interested other marijuana entities such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) and other states looking to improve their cannabis markets.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com